Medlab Clinical Limited (MDC:ASX)
Medlab Clinical Limited is an Australian biotechnology company. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. The Nutraceutical segment is engaged in the supply of Medlab’s self-branded nutraceutical range, predominantly in Australia. The Pharmaceutical Research segment is engaged in research activities, which includes depression and oncology, and the supply of cannabis-based medicines. Its pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead candidate is NanaBis, which targets for the treatment of bone pain in breast and prostate cancer patients. Its NanoCelle is designed to address known medication problems and addressing global unmet medical needs. The Company's products include NanaBidial, NanoCBD, and MgOptima and CBD.